Search results
Results from the WOW.Com Content Network
Blood compatibility testing is routinely performed before a blood transfusion.The full compatibility testing process involves ABO and RhD (Rh factor) typing; screening for antibodies against other blood group systems; and crossmatching, which involves testing the recipient's blood plasma against the donor's red blood cells as a final check for incompatibility.
These tests may establish a platelet count. Newer automated platelet pheresis machines do that as the donation begins, and adjust accordingly the quantity of platelets to be drawn. Tests may also determine the donor's compatibility with particular recipients through a human leukocyte antigen (HLA) test.
Platelet satellitism. Platelet rosetting, or satelliting, around white blood cells can lead to undercounting by automated analyzers. [5] Clotted samples. Coagulation within the sample leads to undercounting, because the analyzer samples the liquid part of the blood, while some of the platelets remain in the tube, trapped in the clot.
Cross-matching or crossmatching is a test performed before a blood transfusion as part of blood compatibility testing. Normally, this involves adding the recipient's blood plasma to a sample of the donor's red blood cells. If the blood is incompatible, the antibodies in the recipient's plasma will bind to antigens on the donor red blood cells.
Platelet transfusions came into medical use in the 1950s and 1960s. [1] [5] It is on the World Health Organization's List of Essential Medicines. [6] [7] Some versions of platelets have had the white blood cells partially removed or been gamma irradiated which have specific benefits for certain populations. [8]
Reactive thrombocythemia is the most common cause of a high platelet count. It accounts for 88% to 97% of thrombocythemia cases in adults, and near 100% in children. In adults, acute infection, tissue damage, chronic inflammation and malignancy are the common causes of reactive thrombocythemia. Usually, one or more of these conditions is ...
In a phase 1-2 open-label study treatment with CM313, a novel anti-CD38 monoclonal antibody, rapidly boosted platelet levels in adults with ITP by inhibiting antibody-dependent cell-mediated cytotoxicity on platelets; maintained long-term efficacy by clearing plasma cells; and was associated with low-grade toxic effects.
Tests in platelet poor plasma or in platelet free plasma (convenient for transportation; can be frozen; possibility to use optical observation methods; but the thrombocyte component of the hemostasis is not taken into account), Tests in platelet rich plasma (close to real conditions in the body, but restrictions as to the terms of work),